{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:38:10Z","timestamp":1777930690797,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8\u201314 migraine headache days\/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acute treatment overuse versus those with low-frequency EM (LFEM: 4\u20137 migraine headache days\/month). In this post hoc analysis, we assessed the proportions of patients who shifted from HFEM to LFEM and to very low-frequency EM (VLFEM: 0\u20133 migraine headache days\/month) status following treatment with galcanezumab versus placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EVOLVE-1 and EVOLVE-2 were double-blind, Phase 3 studies in patients with EM. Patients (18\u201365\u2009years) were randomized (2:1:1) to subcutaneous monthly injections of placebo, galcanezumab 120\u2009mg (240\u2009mg loading dose) or 240\u2009mg, for up to 6\u2009months. Data were pooled and endpoints were change from baseline in number of migraine headache days\/month and patients who shifted from HFEM to LFEM or VLFEM status. Impact of change in HFEM status on migraine headache days\/month, quality of life and disability was also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 66% (1176\/1773) patients from EVOLVE studies had HFEM status at baseline and were included in this analysis; placebo: 592, galcanezumab 120\u2009mg: 294 and galcanezumab 240\u2009mg: 290. At each month, both doses of galcanezumab resulted in a higher proportion of patients who shifted to 0\u20137 monthly headache days\/month (VLFEM or LFEM status). Patients who shifted from HFEM at baseline to VLFEM status at Month 3, a relatively larger proportion of patients on galcanezumab 120\u2009mg versus placebo remained at VLFEM status at Months 4\u20136; Months 4\u20135 for galcanezumab 240\u2009mg versus placebo. Among the galcanezumab-treated patients who did-not-shift or shifted to LFEM or VLFEM status for \u22653 consecutive months until the end of the study, patients who shifted from HFEM to VLFEM status experienced the largest reduction in migraine headache days\/month and the largest clinically meaningful improvements in daily functioning (MSQ-RFR) and disability (MIDAS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with HFEM, treatment with galcanezumab (120\u2009mg and 240\u2009mg) significantly reduced migraine headache days\/month, maintained remission status at subsequent months until the end of the study, and improved patients\u2019 quality of life versus placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> Identifier: EVOLVE-1, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02614183\">NCT02614183<\/jats:ext-link>; EVOLVE-2, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02614196\">NCT02614196<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01222-w","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T09:34:59Z","timestamp":1622194499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7291-3632","authenticated-orcid":false,"given":"Jakub","family":"Jedynak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Eross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallikarjuna","family":"Rettiganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia L.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"1222_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"G. B. D. Neurological Disorders Collaborator Group","year":"2017","unstructured":"G. B. D. Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16:877\u2013897","journal-title":"Lancet Neurol"},{"issue":"8","key":"1222_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10194-012-0482-1","volume":"13","author":"A Raggi","year":"2012","unstructured":"Raggi A, Giovannetti AM, Quintas R, D\u2019Amico D, Cieza A, Sabariego C, Bickenbach JE, Leonardi M (2012) A systematic review of the psychosocial difficulties relevant to patients with migraine. J Headache Pain 13(8):595\u2013606. https:\/\/doi.org\/10.1007\/s10194-012-0482-1","journal-title":"J Headache Pain"},{"issue":"1","key":"1222_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0333102415580099","volume":"36","author":"N Abu Bakar","year":"2016","unstructured":"Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M (2016) Quality of life in primary headache disorders: a review. Cephalalgia. 36(1):67\u201391. https:\/\/doi.org\/10.1177\/0333102415580099","journal-title":"Cephalalgia."},{"issue":"Suppl 1","key":"1222_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10072-013-1378-9","volume":"34","author":"D D'Amico","year":"2013","unstructured":"D'Amico D, Grazzi L, Usai S, Leonardi M, Raggi A (2013) Disability and quality of life in headache: where we are now and where we are heading. Neurol Sci 34(Suppl 1):S1\u2013S5","journal-title":"Neurol Sci"},{"issue":"10","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 57(10):1532\u20131544. https:\/\/doi.org\/10.1111\/head.13202","journal-title":"Headache."},{"issue":"1","key":"1222_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-019-1024-x","volume":"20","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20(1):75. https:\/\/doi.org\/10.1186\/s10194-019-1024-x","journal-title":"J Headache Pain"},{"issue":"4","key":"1222_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","volume":"22","author":"RJ Benschop","year":"2014","unstructured":"Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, Nelson J, Gaynor B, Xu J, Wang XF, Lynch RA, Li B, McCarty D, Nisenbaum ES, Oskins JL, Lin C, Johnson KW, Chambers MG (2014) Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr Cartil 22(4):578\u2013585. https:\/\/doi.org\/10.1016\/j.joca.2014.01.009","journal-title":"Osteoarthr Cartil"},{"issue":"9","key":"1222_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/head.13427","volume":"58","author":"N Rosen","year":"2018","unstructured":"Rosen N, Pearlman E, Ruff D, Day K, Jim NA (2018) 100% response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE-1 and EVOLVE-2 studies. Headache. 58(9):1347\u20131357. https:\/\/doi.org\/10.1111\/head.13427","journal-title":"Headache."},{"issue":"9","key":"1222_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"issue":"8","key":"1222_CR10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 38(8):1442\u20131454. https:\/\/doi.org\/10.1177\/0333102418779543","journal-title":"Cephalalgia."},{"issue":"1","key":"1222_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S Forderreuther","year":"2018","unstructured":"Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19(1):121. https:\/\/doi.org\/10.1186\/s10194-018-0951-2","journal-title":"J Headache Pain"},{"issue":"9","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache S","year":"2013","unstructured":"Headache Classification Committee of the International Headache S (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 33(9):629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658","journal-title":"Cephalalgia."},{"issue":"5","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","volume":"22","author":"R Rendas-Baum","year":"2013","unstructured":"Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the migraine-specific quality of life questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22(5):1123\u20131133. https:\/\/doi.org\/10.1007\/s11136-012-0230-7","journal-title":"Qual Life Res"},{"issue":"7","key":"1222_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s11136-007-9217-1","volume":"16","author":"JC Cole","year":"2007","unstructured":"Cole JC, Lin P, Rupnow MF (2007) Validation of the migraine-specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 16(7):1231\u20131237. https:\/\/doi.org\/10.1007\/s11136-007-9217-1","journal-title":"Qual Life Res"},{"issue":"5","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1212\/WNL.0000000000007856","volume":"93","author":"JH Ford","year":"2019","unstructured":"Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V, Aurora SK, Tockhorn-Heidenreich A, Lipton RB (2019) Two randomized migraine studies of galcanezumab: effects on patient functioning and disability. Neurology. 93(5):e508\u2013e517. https:\/\/doi.org\/10.1212\/WNL.0000000000007856","journal-title":"Neurology."},{"issue":"2","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 19(2):107\u2013114; discussion 174. https:\/\/doi.org\/10.1046\/j.1468-2982.1999.019002107.x","journal-title":"Cephalalgia."},{"issue":"Supplement 1","key":"1222_CR17","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 56(Supplement 1):S20\u2013S28. https:\/\/doi.org\/10.1212\/WNL.56.suppl_1.S20","journal-title":"Neurology."},{"issue":"1","key":"1222_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11916-013-0385-0","volume":"18","author":"M Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet M (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18(1):385. https:\/\/doi.org\/10.1007\/s11916-013-0385-0","journal-title":"Curr Pain Headache Rep"},{"issue":"mar24 5","key":"1222_CR19","doi-asserted-by":"publisher","first-page":"g1416","DOI":"10.1136\/bmj.g1416","volume":"348","author":"TJ Schwedt","year":"2014","unstructured":"Schwedt TJ (2014) Chronic migraine. BMJ. 348(mar24 5):g1416. https:\/\/doi.org\/10.1136\/bmj.g1416","journal-title":"BMJ."},{"issue":"4","key":"1222_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81(4):428\u2013432. https:\/\/doi.org\/10.1136\/jnnp.2009.192492","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 2","key":"1222_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 55(Suppl 2):103\u2013122; quiz 123-106. https:\/\/doi.org\/10.1111\/head.12505_2","journal-title":"Headache."},{"issue":"8","key":"1222_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","volume":"76","author":"A Manack","year":"2011","unstructured":"Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB (2011) Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 76(8):711\u2013718. https:\/\/doi.org\/10.1212\/WNL.0b013e31820d8af2","journal-title":"Neurology."},{"issue":"5","key":"1222_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, on behalf of the AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68(5):343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology."},{"issue":"10","key":"1222_CR24","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1179\/1743132813Y.0000000244","volume":"35","author":"SK Bhoi","year":"2013","unstructured":"Bhoi SK, Kalita J, Misra UK (2013) Is 6 months of migraine prophylaxis adequate? Neurol Res 35(10):1009\u20131014. https:\/\/doi.org\/10.1179\/1743132813Y.0000000244","journal-title":"Neurol Res"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T09:35:01Z","timestamp":1622194501000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01222-w","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were conducted in concordance with the ethical principles that have their origin in the Declaration of Helsinki guidelines. All patients provided written informed consent before study participation. The study protocols, for both the studies, were reviewed and approved by the Institutional Review Board, Medical Ethics Committee or Medical Research and Ethics Committee of the participating study sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jakub Jedynak, Virginia L. Stauffer, Mallik Rettiganti are employees of Eli Lilly and Company and\/or its subsidiaries and hold company stock. Dr. Gendolla receives fees for ad boards, lectures and participation in clinical trials from Pharm Allergan, Reckitt Benckiser, Bayer, Gr\u00fcnenthal, Mundipharma, Novartis, Eli Lilly and Company, Teva, Sanofi and Hormosan. Eric Eross is a consultant and is a member of the speaker bureau at Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}